Intraperitoneal Injection Of Zymosan Research Articles

Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E 2

Intraperitoneal injection of zymosan in mice induced rapid extravasation and accumulation of plasma proteins in the peritoneal cavity. Neutrophils began to appear in the peritoneal cavity after a lag period of approximately 3 hours. The injected mice exhibited a pain response (writhing) during the first 30 minutes after injection, but writhing ceased before protein or cell accumulation had reached maximum levels. The injection of zymosan induced synthesis of PGE 2 (measured by RIA) which reached maximum levels of 30 minutes, then declined slowly. Peptido-leukotriene levels (detected by bioassay, RIA and HPLC) increased rapidly after injection, reached a peak within an hour of injection and declined to undetectable levels within 4 hours. The early peptido-LT was predominantly LTC 4, while later, LTE 4 was the major component. LTD 4 levels remained low throughout and no LTB 4 was detected at any time. Indomethacin treatment elevated levels of peptido-LTs, recued PGE 2 levels and inhibited writhing. Phenidone reduced peptido-LT levels. In vitro studies demonstrated that zymosan stimulates LTC4 synthesis by peritoneal cells whereas LTE 4, LTD 4, LTB 4 or monoHETES were not detectable (using HPLC methods). The source of enzymes responsible for the in vivo metabolism of LTC 4 to LTD 4 and LTE 4 could not be identified.

The effects of zymosan upon the mast cell population of the peritoneal fluid.

SummaryA single intraperitoneal injection of zymosan into rats resulted in the engulfment of these particles by mast cells as well as by macrophages. There was a rapid fall in the numbers of free-floating mast cells which appeared to be a result of cellular clumping, and the numbers of peritoneal fluid mast cells remained depressed for at least 40 days. Unlike rats, neither mice, hamsters, nor gerbils displayed large scale engulfment of zymosan by peritoneal fluid mast cells.